Deepu Madduri, MD, qualified at the University of Oklahoma College of Medicine before completing an internal medicine residency at St. Mary Medical Center, Langhorne, PA, and fellowship in hematology and oncology at the University of California. She received additional fellowship training in blood and marrow transplant at Stanford Hospital.
Dr Madduri is an Associate Professor of Medicine at the Mount Sinai Hospital, New York, NY. Her current roles include Associate Director of the Cellular Therapy Service, Director of Clinical Operations for the Multiple Myeloma Program, and Program Lead for Foundation Medicine’s Smart Trials Precision Enrollment Program.
Speaking on novel immunotherapy clinical trials in multiple myeloma
Dr Madduri has a wealth of experience in plasma cell disorders. While most of her work focuses on relapsed/refractory multiple myeloma, she also conducts research into light chain amyloidosis, POEMS syndrome, plasmacytoma and monoclonal gammopathy of unknown significance. Dr Madduri has been involved in pioneering research surrounding the clinical management of myeloma. Her expertise in plasma cell dyscrasias and transplantation has seen her involved in numerous first-in-human and Phase I immunotherapy clinical trials, specifically, investigating checkpoint inhibitors, cellular therapies and bispecific antibodies. Dr Madduri’s work has been integral to initiating CAR-T studies in myeloma.